Cargando…

Relationship between PD-L1 expression and molecular aberrances in lung adenocarcinoma with solid components

BACKGROUND: Previous studies have evaluated the expression of programmed cell death ligand 1 (PD-L1) in terms of genetic mutation in lung adenocarcinoma (LUAD). However, there are no corresponding large-sample studies in Chinese patients with LUAD with solid components (LUAD-SC). Furthermore, it rem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Kun, Zou, Yining, Zhao, Li, Tao, Yunlan, Lu, Shaohua, Hou, Yingyong, Chen, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323584/ https://www.ncbi.nlm.nih.gov/pubmed/37426139 http://dx.doi.org/10.21037/jtd-22-1095

Ejemplares similares

Solid histological component of adenocarcinoma might play an important role in PD‐L1 expression of lung adenocarcinoma
por: Miyazawa, Tomoyuki, et al.
Publicado: (2021)

Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component
por: Suzuki, Masaki, et al.
Publicado: (2021)

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
por: Suda, Kenichi, et al.
Publicado: (2019)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
por: Cai, Yiran, et al.
Publicado: (2020)

Prognostic impact of highly solid component in early-stage solid lung adenocarcinoma
por: Kato, Taketo, et al.
Publicado: (2023)

Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival
por: Svensson, Maria C., et al.
Publicado: (2019)

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
por: Weng, Yi Ming, et al.
Publicado: (2018)

Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2016)

Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms
por: Ma, Jianli, et al.
Publicado: (2018)

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis
por: Huang, Shuang, et al.
Publicado: (2023)

The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series
por: Wu, Jianghua, et al.
Publicado: (2019)

Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment
por: Su, Qiang, et al.
Publicado: (2018)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

A Rare Case of Moderately Differentiated Adenocarcinoma With PD-L1 Overexpression and a Heterogeneous LELC Component in the Ascending Colon
por: Nagano, Hideki, et al.
Publicado: (2020)

Prostate Adenocarcinomas Aberrantly Expressing p63 Are Molecularly Distinct from Usual-Type Prostatic Adenocarcinomas
por: Tan, Hsueh-Li, et al.
Publicado: (2014)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features
por: Watari, Jiro, et al.
Publicado: (2019)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

PD-L1 and Survival in Solid Tumors: A Meta-Analysis
por: Wu, Pin, et al.
Publicado: (2015)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung
por: Janzic, Urska, et al.
Publicado: (2017)

Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma
por: Li, Zhihua, et al.
Publicado: (2022)

Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components
por: Wang, Li-Li, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Wang, Miao, et al.
Publicado: (2021)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
por: Tomlins, Scott A., et al.
Publicado: (2023)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma
por: Shimizu, Katsuhiko, et al.
Publicado: (2017)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
por: Zhang, Yue, et al.
Publicado: (2022)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
por: Göbel, Holger H., et al.
Publicado: (2022)

Prognostic value of PD –L1 expression in patients with primary solid tumors
por: Xiang, Xiao, et al.
Publicado: (2017)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Genomic Aberrations in Lung Adenocarcinoma in Never Smokers
por: Job, Bastien, et al.
Publicado: (2010)

Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy
por: Cui, Yuehong, et al.
Publicado: (2012)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

Relationship between PD-L1 expression and (18)F-FDG uptake in gastric cancer
por: Chen, Ruohua, et al.
Publicado: (2019)

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
por: Chen, Yanhui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_471c5n1kg9mhkaql3ofm6n9fdg